Screening of Exons 4-9 Polymorphisms of Gene in Endometrial and Ovarian Cancers

Overview

Journal Arch Razi Inst

Specialties Allergy & Immunology
General Medicine
Veterinary Medicine

Date 2023 Jun 14

PMID 37312707

Authors

M Khudheyer Almyah

A N Ayyob

R A Al-Badran

A Issa Al-Badran

Affiliations

Soon will be listed here.

Abstract

Endometrial and ovarian tumours are almost mechanistically affected by reproductive hormones. Ovarian cancer may be explained as metastatic or synchronous primary ovarian cancer, and the specific diagnosis is a challenge. This study aimed to investigate the mutations in fat mass and obesity-associated () genes and investigated the association of these mutations with the risk of endometrial and ovarian cancers as well as with cancer grade and stage. Blood samples were collected from 48 endometrial and ovarian cancer cases and 48 healthy women. Genomic DNA was extracted, and PCR was done to amplify exons 4-9. Sanger sequencing identified 6 different novel mutations submitted to DDBJ: p.W278G and p.G284G in exon 4, p.S318I and p.A324G in exon 5 and two mutations in intron 4. Other mutations were also detected in gene sequencing results, rs112997407 in intron 3, rs62033438, rs62033439, rs8048254 and rs8046502 in intron 4. The novel p.W278G, p.S318I and p.A324G mutations were predicted to be damaging. We did not find a significant association for all variables with cancer risk or clinical stage and grade except for rs62033438 variants, which showed a significant association with cancer grade, especially AA genotype (OR= 15, 95% CI:1.32 -169.88, = 0.03). In conclusion, the statistical analysis did not clarify whether mutations are implicated in cancer. Further studies with more samples are recommended to provide a more accurate picture of the correlation between mutations and endometrial and ovarian cancer susceptibility.

References

Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y . FTO-Dependent -Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling. Cancer Res. 2020; 80(16):3200-3214. PMC: 7442742. DOI: 10.1158/0008-5472.CAN-19-4044. View

Reitz C, Tosto G, Mayeux R, Luchsinger J . Genetic variants in the Fat and Obesity Associated (FTO) gene and risk of Alzheimer's disease. PLoS One. 2012; 7(12):e50354. PMC: 3520931. DOI: 10.1371/journal.pone.0050354. View

Loos R, Bouchard C . FTO: the first gene contributing to common forms of human obesity. Obes Rev. 2008; 9(3):246-50. DOI: 10.1111/j.1467-789X.2008.00481.x. View

Mojaver M, Mokarian F, Kazemi M, Salehi M . Specific TaqMan allelic discrimination assay for rs1477196 and rs9939609 single nucleotide polymorphisms of FTO gene demonstrated that there is no association between these SNPs and risk of breast cancer in Iranian women. Adv Biomed Res. 2015; 4:136. PMC: 4544116. DOI: 10.4103/2277-9175.161532. View

Zhao Z, Wen W, Michailidou K, Bolla M, Wang Q, Zhang B . Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control. 2016; 27(5):679-93. PMC: 5029371. DOI: 10.1007/s10552-016-0741-6. View

Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y . N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011; 7(12):885-7. PMC: 3218240. DOI: 10.1038/nchembio.687. View

Toh J, Sun L, Lau L, Tan J, Low J, Tang C . A strategy based on nucleotide specificity leads to a subfamily-selective and cell-active inhibitor of -methyladenosine demethylase FTO. Chem Sci. 2017; 6(1):112-122. PMC: 5424463. DOI: 10.1039/c4sc02554g. View

Zhou S, Bai Z, Xia D, Zhao Z, Zhao R, Wang Y . FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation. Mol Carcinog. 2018; 57(5):590-597. DOI: 10.1002/mc.22782. View

Adzhubei I, Schmidt S, Peshkin L, Ramensky V, Gerasimova A, Bork P . A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7(4):248-9. PMC: 2855889. DOI: 10.1038/nmeth0410-248. View

10.

Zhu Y, Shen J, Gao L, Feng Y . Estrogen promotes fat mass and obesity-associated protein nuclear localization and enhances endometrial cancer cell proliferation via the mTOR signaling pathway. Oncol Rep. 2016; 35(4):2391-7. DOI: 10.3892/or.2016.4613. View

11.

Olszewski P, Fredriksson R, Olszewska A, Stephansson O, Alsio J, Radomska K . Hypothalamic FTO is associated with the regulation of energy intake not feeding reward. BMC Neurosci. 2009; 10:129. PMC: 2774323. DOI: 10.1186/1471-2202-10-129. View

12.

Lin Y, Yan M, Shih Y, Hsieh C . The basal body gene, RPGRIP1L, is a candidate tumour suppressor gene in human hepatocellular carcinoma. Eur J Cancer. 2009; 45(11):2041-9. DOI: 10.1016/j.ejca.2009.04.012. View

13.

Zeng X, Ban Z, Cao J, Zhang W, Chu T, Lei D . Association of FTO Mutations with Risk and Survival of Breast Cancer in a Chinese Population. Dis Markers. 2015; 2015:101032. PMC: 4471376. DOI: 10.1155/2015/101032. View

14.

Chen J . Multiple signal pathways in obesity-associated cancer. Obes Rev. 2011; 12(12):1063-70. DOI: 10.1111/j.1467-789X.2011.00917.x. View

15.

Lin Y, Ueda J, Yagyu K, Ishii H, Ueno M, Egawa N . Association between variations in the fat mass and obesity-associated gene and pancreatic cancer risk: a case-control study in Japan. BMC Cancer. 2013; 13:337. PMC: 3716552. DOI: 10.1186/1471-2407-13-337. View

16.

Gerken T, Girard C, Tung Y, Webby C, Saudek V, Hewitson K . The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007; 318(5855):1469-72. PMC: 2668859. DOI: 10.1126/science.1151710. View

17.

Zhang Z, Zhou D, Lai Y, Liu Y, Tao X, Wang Q . Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways. Cancer Lett. 2012; 319(1):89-97. DOI: 10.1016/j.canlet.2011.12.033. View

18.

Huang H, Weng H, Sun W, Qin X, Shi H, Wu H . Recognition of RNA N-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018; 20(3):285-295. PMC: 5826585. DOI: 10.1038/s41556-018-0045-z. View

19.

Zheng Z, Hong L, Huang X, Yang P, Li J, Ding Y . Screening for coding variants in FTO and SH2B1 genes in Chinese patients with obesity. PLoS One. 2013; 8(6):e67039. PMC: 3692548. DOI: 10.1371/journal.pone.0067039. View

20.

Oranratanaphan S, Manchana T, Sirisabya N . Clinicopathologic variables and survival comparison of patients with synchronous endometrial and ovarian cancers versus primary endometrial cancer with ovarian metastasis. Asian Pac J Cancer Prev. 2008; 9(3):403-7. View